Drugs / Azacitadine
Azacitadine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02265731 | Sep 2014 → Mar 2021 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma | AbbVie | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04480099 | Jul 2020 → Apr 2023 | peripheral T-cell lymphoma, not otherwise specified | Ruijin Hospital | Unknown | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT02319135 | Oct 2014 → Oct 2018 | acute myeloid leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06651229 Background | Mar 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Press releases naming this drug 17 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | azacitadine | “Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation.” NCT04480099 ↗ |
| Known as | AZA | “Azacitadine (AZA)” NCT06651229 ↗ |
| Known as | Azacitidine | “Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7.” NCT02319135 ↗ |
| Known as | azacytidine | “comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA).” PMID 34070172 ↗ May 2021 |
| Known as | Vidaza | “Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine” NCT02319135 ↗ |
| Route | Intravenous | “by IV infusion” NCT02265731 ↗ |